# Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

> **NCT01111305** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 31 (actual)

## Conditions studied

- Loiasis

## Interventions

- **DRUG:** Reslizumab
- **DRUG:** Diethylcarbamazine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01111305
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2016-01
- **Final completion:** 2017-09
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01111305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01111305, "Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01111305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*